Skip to main content
Equibles
APUS logo

APUS · Apimeds Pharmaceuticals US, Inc. · Investor Relations

Track APUS — free

Use APUS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research APUS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.71 -0.03 (-0.92%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$4.08M
Shares
1.51M
Volume · Nov 6 16.69K Avg daily vol (3M) 3.7M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Key facts CIK 1894525 CUSIP 03771D201 13F (30d) 1 filings 1 filers Visit website